Clinical Trial Results: Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab [Phase 2]

View source ↗

Summary

Phase 2 study evaluating TLR9 agonist vidutolimod (CMP-001) in combination with nivolumab versus nivolumab alone in melanoma; results completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Vidutolimod
• nivolumab (nivolumab)

Snippet

Sponsor: Diwakar Davar | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2026-07-02